Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker
Source: SeekingAlpha
2026-02-28 08:58:59 ET
I have followed and chronicled the ups and downs of ACADIA Pharmaceuticals ( ACAD ) since 07/2017's "Acadia: Order For Central Nervous Systems In Need". My most recent Acadia article focusing exclusively on Acadia was 10/2022's "Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah" (" Last Hurrah "). Since Last Hurrah, which rated Acadia as a "hold," Acadia's price has risen a nice 57%, or a little more than 16% a year....
Read the full article on Seeking Alpha
For further details see:
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker
ACADIA Pharmaceuticals Inc.
NASDAQ: ACAD
ACAD Trading
-5.13% G/L:
$21.65 Last:
508,159 Volume:
$22.04 Open:
ACAD Latest News
March 03, 2026 04:05:00 pm
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
March 02, 2026 04:05:00 pm
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
February 26, 2026 09:35:00 am
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments
ACAD Stock Data
$3,864,112,700
124,348,635
0.05%
128
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
